Reducing Cardiovascular Risk in T2DM with SGLT2 Inhibitors and GLP1-Receptor Agonists: Translating Evidence into Patient Outcomes
Free to AADE Members
Annual Meeting Symposium, 60 minutes
Effective dates for CE credit: 8/19/18 – 11/26/20
1.0 CE credits
Despite the availability of multiple therapeutic classes, the majority of conventional antidiabetic agents fail to address macrovascular risk factors and subsequent complications associated with type 2 diabetes mellitus (T2DM). As such, cardiovascular disease (CVD) remains the leading cause of death among people living with T2DM. Fortunately, emerging clinical evidence demonstrates that novel antidiabetic agents, such as sodium-glucose co-transport-2 (SGLT-2) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) not only improve glycemic control and microvascular complications but also demonstrate meaningful clinical impacts on CVD risk reduction.
Ensuring that these advances translate into real-world benefits for people with T2DM relies on the identification of people who are most likely to benefit from novel agents and their appropriate use as part of individualized treatment paradigms, the management of potential treatment-related adverse events, and importantly, the requirement of individuals to be persistent with these therapies as part of multimodal CV risk reduction strategies.
This symposium reviews the latest data on cardiovascular outcomes related to use of SGLT-2 inhibitors and GLP-1RAs, among other blood sugar lowering agents, the impact of available and emerging data on care and clinical outcomes. Importantly, this activity addresses practical diabetes educator-driven strategies to optimize the appropriate use of novel agents as part of T2DM and CVD self-management.
This recording of a live presentation is a knowledge-based learning activity.
At the end of this presentation, the participant will be able to:
- Recognize the efficacy, safety, and impact of SGLT-2 inhibitors and GLP-1RAs in reducing micro- and macrovascular disease and nephropathy.
- Identify individuals living with diabetes who are likely to benefit from pharmacological agents that reduce micro- and macrovascular risk reduction as part of individualized T2DM treatment strategies.
- Propose techniques to provide specific education to individuals living with diabetes regarding the use of SGLT-2 inhibitors and GLP-1RAs as part of micro- and macrovascular risk reduction strategies.
The purpose of this activity is to enable the
learner to identify and educate appropriate indivduals for effective, safe use of SGLT-2 inhibitors and GLP-1 receptor agonists in reducing microvascular and macrovascular disease including nephropathy.
This is a knowledge-based activity designed for individual or groups of diabetes educators, including RNs, RDs, Pharmacists, Nurse Practitioners, Clinical Nurse Specialists, Physician Assistants, MDs, and other health care providers interested in staying up to date on current practices of care for their patients with diabetes and other related conditions.
Jack Leahy, MD
Co-Chief Division of Endocrinology, Diabetes, and Metabolism
University of Vermont
Erica Hall, MSN, ANP-BC, CDE
Division of Endocrinology, Diabetes, and Metabolism
Johns Hopkins University School of Medicine
This program is supported by an educational funding provided by AstraZeneca Pharmaceuticals LP.
Continuing Education Credit
This educational program will provide 1.0 contact hours of continuing education credit. To successfully complete the program to earn CE credit, learners must view the recorded session in its entirety, successfully complete short pre- and post-learning assessments, and submit an evaluation survey. A continuing education statement of credit will be provided online.
The American Association of Diabetes Educators is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
This educational program will provide 1.0 contact hours of continuing education credit.
AADE is accredited as a provider of continuing nursing education by the California Board of Registered Nursing (CEP # 10977).
The American Association of Diabetes Educators, (AM001) is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). Registered dietitians (RDs) and dietetic technicians, registered (DTRs) will receive 1.0 continuing professional education units (CPEUs) for completion of this program. Continuing Professional Education Provider Accreditation does not constitute endorsement by CDR of a provider, program, or materials.
The American Association of Diabetes Educators is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This program provides 1.0 contact hours (0.10 CEUs) of continuing education credit.
ACPE Universal Program Number: 0069-9999-18-129-H01-P
Effective Dates: 8/19/18 – 11/26/2020
It is the policy of the American Association of Diabetes Educators to require that anyone who has an opportunity to affect continuing education activities content (e.g. authors, presenters and program planners) with products or services from a commercial interest with which s/he has financial relationships, discloses those financial relationship/s with commercial entities to participants.
Disclosure of a relationship is not intended to suggest or condone bias in any presentation, but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.
Relevant disclosures (or lack thereof) among educational activity faculty and planners are as follows.
- Jack L. Leahy, MD: Consultant – Janssen Pharmaceuticals Inc, Merck & Co Inc, and Novo Nordisk.
- Erica L. Hall, MSN, ANP-BC, CDE, has no relevant financial disclosures to report.
- Jodi Lavin-Tompkins, MSN, RN, CDE, BC-ADM, AADE, has no relevant financial disclosures to report.
- Joanne Rinker, MS, RD, CDE, LDN, FAADE, AADE, has no relevant financial disclosures to report.
- Adrienne Roser, ASiM, has no relevant financial disclosures to report.
- Jeffrey Stein, ASiM, has no relevant financial disclosures to report.
The approval of this educational offering by the AADE does not imply endorsement of specific therapies, treatments, or products discussed in the presentations. Any discussion of off-label use or investigational information is disclosed to the learners during the presentation.
Originally presented on: 8/19/2018
Expiration date: 11/26/2020
You will have access to this learning activity for a period of six months after you enroll, or whenever the activity's CE credits expire (whichever comes first).
Volume discounts are available and will be automatically applied at check-out when the desired quantity is selected
-- Groups of 4-9: 10% off
-- Groups of 10-19: 20% off
-- Groups of 20-29: 30% off
-- Groups of 30+ and Members: Contact firstname.lastname@example.org to get a custom quote.